MGR Webcast - Targeting IL11 in Fibrotic Diseases: From Publication to Clinical Trial in Five Years

We are excited to offer Medicine Grand Rounds in a virtual format per University restrictions on large meetings. Please do not attend in person but make sure to watch this presentation on your computers or devices. "Targeting IL11 in Fibrotic Diseases: From Publication to Clinical Trial in Five Years" Stuart Cook, MD, PhD Professor at Imperial College, London and Duke-NUS Dr. Cook is a Professor at Imperial College, London and Duke-NUS. His team helped define the central role of titin in dilated cardiomyopathy and developed a gene-based test for inherited cardiac conditions that was commercialised by Illumina and is now used in clinical practice worldwide. His group discovered a critical role for the IL11 cytokine in fibrosis, inflammation and tissue regeneration. He is a co-founder of Enleofen, a biotechnology company that developed first-in-class antibody therapeutics against IL11. Enleofen's therapeutic platform was acquired by Boehringer Ingelheim in the largest Biotechnology deal from Singapore in late 2019. The overarching goal of his research is to understand disease mechanisms and to translate basic science discoveries to healthcare. Find the Zoom meeting details here: https://med